01 / Customer question
The commercial context
Evidence, audience and intended use change the requirements.
Provider discovery, patient education, professional medical information and clinical systems serve different purposes. The evidence and controls required for one should not be assumed to suit the others. Audience, market and intended use shape the assessment.
Outdated evidence, unsupported indications and omitted limitations can materially change the meaning of an answer. We assess public representation against approved information with the appropriate specialists. Private knowledge and administrative use cases are considered separately, with permissions and review defined before a pilot.
Customer journeys
Assess patient, professional and scientific journeys separately.
We build the assessment around specific questions, audiences and markets. These examples show the kinds of journeys we can examine; the final scope follows your priorities.
02 / Customer question
Does a treatment/device explanation preserve indications, evidence dates and material limitations?
03 / Customer question
Can an authorised professional retrieve the correct scientific or medical reference with traceable evidence?
How SWLR can help
Evaluate information quality with the right reviewers.
01
Discovery and representation
We scope provider, therapeutic-area or device journeys for the selected audience and market. The findings identify representation gaps without treating patient and professional questions as interchangeable.
You receive: Representation baseline and audience-specific gaps.
02
Evidence and approved-content evaluation
We compare material claims with approved information and specialist-reviewed evidence. The assessment records reference dates, applicability and limitations, and identifies information needing an update or further qualified review.
You receive: Evidence/claims map, error register and update priorities.
03
Private workflow readiness
We assess medical, scientific or administrative knowledge for permissioned assistance. The plan identifies data lineage, reviewer roles and a suitable task scope, with clinical or regulated validation requirements handled separately.
You receive: Knowledge architecture, evaluation scope and adoption roadmap.
Internal AI readiness
Prepare knowledge workflows for appropriate specialist oversight.
Patient and HCP access, medical or regulatory approval and quality processes need named owners. We assess the knowledge, records and workflow changes required for the intended task, preserving the boundary between retrieval, assistance and a clinical decision.
Rights-cleared scientific information may support a separate licensing discussion. Patient records are not a generic monetisation asset. Pilots need traceable evidence, appropriate review and escalation; production clinical systems require additional specialist scope and validation beyond general consulting.
A practical first engagement
Health AI Information & Readiness Assessment
We choose a provider, pharmaceutical, biotechnology or device track, then agree the market, audience, services or products and approved references. You receive material-quality findings, evidence and access gaps, specialist dependencies and a prioritised roadmap for information changes or suitable workflow pilots.
01
Agree the scope
We define the business questions, references, AI surfaces and teams involved. Access requirements and dependencies are agreed before the assessment begins.
02
Review the evidence together
Findings distinguish observed answer behaviour from the underlying content, data or workflow issue. Your teams help establish which changes are material and feasible.
03
Choose the next action
The roadmap sets out priorities, owners, dependencies and validation. Where a pilot makes sense, we scope the implementation and evaluation work with the relevant teams.
Evaluation
Measure the changes that matter.
We agree the criteria before making changes. Answer samples are recorded with their questions, market, surface and date. Repeat checks help show patterns within that scope; commercial outcomes and internal workflow gains need their own evaluation with your teams.
Material claim accuracy
Evidence traceability
Audience and access correctness
Reviewed task quality
Part of Ayima
Technical search expertise. Practical enterprise thinking.
SWLR brings an AI visibility and readiness remit to Ayima's enterprise search background. We connect the business question to the content, data, access and technical work behind it, then help teams prioritise the next steps.
Common questions
Before we begin.
Does this include clinical decision tools?
Clinical decision use is a distinct scope requiring the appropriate qualified specialists, intended-use assessment and validation. Public information or administrative assistance can be assessed separately. We define those boundaries before recommending a pilot.
Can we evaluate public AI without sharing patient data?
Yes. Approved public information and agreed references can support a representation assessment without patient records. Private use cases need separately agreed purpose, permissions, reviewers and data handling.
How do you handle conflicting or outdated evidence?
We record reference dates and evidence provenance, identify contradictions and refer material questions to qualified reviewers. The assessment distinguishes an unsupported claim from information that cannot be verified within the available references.
Signal → Evidence → Action
Start with the questions that matter.
Discuss the audience, services or products and specialist reviewers relevant to your assessment.